Tissue microarrays: Leaping the gap between research and clinical adoption

Personalized Medicine

Volumn 10, Issue 5, 2013, Pages 441-451

  Gustavson, Mark D ^a   Rimm, David L ^b   Dolled Filhart, Marisa ^c  

^a Genoptix Inc   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

assay development; biomarker; clinical application; diagnostic testing; digital pathology; quality control; tissue microarray

Indexed keywords

CLINICAL LABORATORY; CLINICAL RESEARCH; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; HUMAN; HYDROLYSIS; IMAGE ANALYSIS; IMMUNOASSAY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; REVIEW; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TRANSLATIONAL RESEARCH;

EID: 84880193098     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.42     Document Type: Review

References (63)

1. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: A new technology for amplification of tissue resources. Cancer J. 7(1), 24-31 (2001
2. Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E. Amplification of tissue by construction of tissue microarrays. Exp. Mol. Pathol. 70(3), 255-264 (2001
3. Giltnane JM, Rimm DL. Technology insight: Identification of biomarkers with tissue microarray technology. Nat. Clin. Pract. Oncol. 1(2), 104-111 (2004
4. Battifora H. The multitumor (sausage) tissue block: Novel method for immunohistochemical antibody testing. Lab. Invest. 55(2), 244-248 (1986
5. Wan WH, Fortuna MB, Furmanski P. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J. Immunol. Methods 103(1), 121-129 (1987
6. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4(7), 844-847 (1998
7. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: Progress in the discovery and validation of cancer biomarkers. J. Clin. Oncol. 26(34), 5630-5637 (2008
8. Dolled-Filhart MP, Gustavson MD. Tissue microarrays and quantitative tissue-based image-analysis as a tool for oncology biomarker and diagnostic development. Expert Opin. Med. Diagn. 6(6), 569-583 (2012
9. Hassan S, Ferrario C, Mamo A, Basik M. Tissue microarrays: Emerging standard for biomarker validation. Curr. Opin. Biotechnol. 19(1), 19-25 (2008
10. Rimm DL, Nielsen TO, Jewell SD et al. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J. Clin. Oncol. 29(16), 2282-2290 (2011
11. Sauter G. Representativity of TMA studies. Methods Mol. Biol. 664, 27-35 (2010
12. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 80(12), 1943-1949 (2000
13. Goethals L, Perneel C, Debucquoy A et al. A new approach to the validation of tissue microarrays. J. Pathol. 208(5), 607-614 (2006
14. Sauter G, Mirlacher M. Tissue microarrays for predictive molecular pathology. J. Clin. Pathol. 55(8), 575-576 (2002
15. Franco R, Caraglia M, Facchini G, Abbruzzese A, Botti G. The role of tissue microarray in the era of target-based agents. Expert Rev. Anticancer Ther. 11(6), 859-869 (2011
16. Simon R, Mirlacher M, Sauter G. Immunohistochemical analysis of tissue microarrays. Methods Mol. Biol. 664, 113-126 (2010
17. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 8(11), 1323-1327 (2002
18. Dolled-Filhart M, Gustavson M, Camp RL, Rimm DL, Tonkinson JL, Christiansen J. Automated analysis of tissue microarrays. Methods Mol. Biol. 664, 151-162 (2010
19. Kallioniemi A. DNA copy number analysis on tissue microarrays. Methods Mol. Biol. 664, 127-134 (2010
20. Rummukainen JK, Salminen T, Lundin J, Joensuu H, Isola JJ. Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab. Invest. 81(11), 1545-1551 (2001
21. Veeck J, Dahl E. RNA expression analysis on formalin-fixed paraffin-embedded tissues in TMA format by RNA in situ hybridization. Methods Mol. Biol. 664, 135-150 (2010
22. Bordeaux JM, Cheng H, Welsh AW et al. Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen. PLoS ONE 7(5), e36559 (2012
23. Hanna JA, Wimberly H, Kumar S, Slack F, Agarwal S, Rimm DL. Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. Biotechniques 52(4), 235-245 (2012
24. Chung JY, Braunschweig T, Hewitt SM. Optimization of recovery of RNA from formalin-fixed, paraffin-embedded tissue. Diagn. Mol. Pathol. 15(4), 229-236 (2006
25. Hewitt SM. Tissue microarrays as a tool in the discovery and validation of predictive biomarkers. Methods Mol. Biol. 823, 201-214 (2011
26. Cantile M, Franco R, Tschan A et al. HOX D13 expression across 79 tumor tissue types. Int. J. Cancer 125(7), 1532-1541 (2009
27. Schlomm T, Chun F, Erbersdobler A. From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer. Methods Mol. Biol. 664, 177-189 (2010
28. Faratian D, Goltsov A, Lebedeva G et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 69(16), 6713-6720 (2009
29. Press MF, Sauter G, Bernstein L et al. Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin. Cancer Res. 11(18), 6598-6607 (2005
30. Dowsett M, Cuzick J, Wale C et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J. Clin. Oncol. 28(11), 1829-1834 (2010
31. Cuzick J, Dowsett M, Pineda S et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki 67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J. Clin. Oncol. 29(32), 4273-4278 (2011
32. Christiansen J, Bartlett JM, Gustavson M et al. Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches. ASCO Annual 2012 Meeting. Chicago, IL, USA, 30 May-3 June 2012 (Abstract 517
33. Zhao S, Natkunam Y. Building 'tissue' microarrays from suspension cells. Methods Mol. Biol. 664, 93-101 (2010
34. Datta MW, Kajdacsy-Balla AA. Tissue microarrays from biopsy specimens. Methods Mol. Biol. 664, 103-111 (2010
35. Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann. Neurol. 65(1), 24-31 (2009
36. Bubendorf L, Kolmer M, Kononen J et al. Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays. J. Natl Cancer Inst. 91(20), 1758-1764 (1999
37. Braunschweig T, Chung JY, Hewitt SM. Tissue microarrays: Bridging the gap between research and the clinic. Expert Rev. Proteomics 2(3), 325-336 (2005
38. Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J. Natl Cancer Inst. 94(11), 852-854 (2002
39. Perez EA, Suman VJ, Davidson NE et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment group N9831 intergroup adjuvant trial. J. Clin. Oncol. 24(19), 3032-3038 (2006
40. Rojo MG, Bueno G, Slodkowska J. Review of imaging solutions for integrated quantitative immunohistochemistry in the pathology daily practice. Folia Histochem. Cytobiol. 47(3), 349-354 (2009
41. Rojo MG, Garcia GB, Mateos CP, Garcia JG, Vicente MC. Critical comparison of 31 commercially available digital slide systems in pathology. Int. J. Surg. Pathol. 14(4), 285-305 (2006
42. Mulrane L, Rexhepaj E, Penney S, Callanan JJ, Gallagher WM. Automated image-analysis in histopathology: A valuable tool in medical diagnostics. Expert Rev. Mol. Diagn. 8(6), 707-725 (2008
43. Mulrane L, Rexhepaj E, Smart V et al. Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: An initial report from the PredTox group. Exp. Toxicol. Pathol. 60(4-5), 235-245 (2008
44. Gustavson MD, Bourke-Martin B, Reilly D et al. Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. Arch. Pathol. Lab. Med. 133(9), 1413-1419 (2009
45. Mengel M, von Wasielewski R, Wiese B, Rüdiger T, Müller-Hermelink HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki 67 labelling index in a large multi-centre trial. J. Pathol. 198(3), 292-299 (2002
46. De la Taille A, Viellefond A, Berger N et al. Evaluation of the interobserver reproducibility of Gleason grading of prostatic adenocarcinoma using tissue microarrays. Hum. Pathol. 34(5), 444-449 (2003
47. Parker RL, Huntsman DG, Lesack DW et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am. J. Clin. Pathol. 117(5), 723-728 (2002
48. Yaziji H, Taylor CR, Goldstein NS et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 16(6), 513-520 (2008
49. Neumeister VM, Sullivan CA, Lindner R et al. Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer. Breast Cancer Res. Treat. 136(1), 67-75 (2012
50. Neumeister VM, Anagnostou V, Siddiqui S et al. Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J. Natl Cancer Inst. 104(23), 1815-1824 (2012
51. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J. Natl Cancer Inst. 88(15), 1054-1059 (1996
52. Divito KA, Charette LA, Rimm DL, Camp RL. Long-term preservation of antigenicity on tissue microarrays. Lab. Invest. 84(8), 1071-1078 (2004
53. Bertheau P, Cazals-Hatem D, Meignin V et al. Variability of immunohistochemical reactivity on stored paraffin slides. J. Clin. Pathol. 51(5), 370-374 (1998
54. Manne U, Myers RB, Srivastava S, Grizzle WE. Re: Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J. Natl Cancer Inst. 89(8), 585-586 (1997
55. Mirlacher M, Kasper M, Storz M et al. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod. Pathol. 17(11), 1414-1420 (2004
56. Chin SF, Daigo Y, Huang HE et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol. Pathol. 56(5), 275-279 (2003
57. Andersen CL, Hostetter G, Grigoryan A, Sauter G, Kallioniemi A. Improved procedure for fluorescence in situ hybridization on tissue microarrays. Cytometry 45(2), 83-86 (2001
58. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod. Pathol. 21(Suppl. 2), S8-S15 (2008
59. Wasielewski R, Hasselmann S, Ruschoff J, Fisseler-Eckhoff A, Kreipe H. Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch. 453(6), 537-543 (2008
60. Fitzgibbons PL, Murphy DA, Hammond ME, Allred DC, Valenstein PN. Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch. Pathol. Lab. Med. 134(6), 930-935 (2010
61. Terry J, Torlakovic EE, Garratt J et al. Implementation of a Canadian external quality assurance program for breast cancer biomarkers: An initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/ Immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 17(5), 375-382 (2009
62. Welsh AW, Moeder CB, Kumar S et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J. Clin. Oncol. 29(22), 2978-2984 (2011
63. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28(16), 2784-2795 (2010